The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming

Introduction: Snakebite is an urgent, unmet global medical need causing significant morbidity and mortality worldwide. Varespladib is a potent inhibitor of venom secretory phospholipase A(2) (sPLA(2)) that can be administered orally via its prodrug, varespladib-methyl. Extensive preclinical data sup...

Descripción completa

Detalles Bibliográficos
Autores principales: Carter, Rebecca W., Gerardo, Charles J., Samuel, Stephen P., Kumar, Surendra, Kotehal, Suneetha D., Mukherjee, Partha P., Shirazi, Farshad M., Akpunonu, Peter D., Bammigatti, Chanaveerappa, Bhalla, Ashish, Manikath, Neeraj, Platts-Mills, Timothy F., Lewin, Matthew R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862656/
https://www.ncbi.nlm.nih.gov/pubmed/36668842
http://dx.doi.org/10.3390/toxins15010022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862656/
https://www.ncbi.nlm.nih.gov/pubmed/36668842
http://dx.doi.org/10.3390/toxins15010022

Ejemplares similares